Big Pharma's feeding frenzy carries on apace: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy
Who is developing drugs for anti-microbial resistance (AMR) and Sepsis?
Something I picked up on this morningโฆfor critical thinkers
This is a big pharma marketing social media post:
๐ ๐๐ก๐ ๐ฅ๐๐ง๐๐ฌ๐๐๐ฉ๐ ๐จ๐ ๐๐๐ง๐๐๐ซ ๐ข๐ฆ๐ฆ๐ฎ๐ง๐จ๐ญ๐ก๐๐ซ๐๐ฉ๐ฒ: PD-1/PD-L1 inhibitors are redefining cancer immunotherapy.
๐ The first PD-1/PD-L1 inhibitors were approved just 10 years ago (Keytruda and Opdivo).
๐ Itโs estimated that more than 700,000 ๐ฉ๐๐ญ๐ข๐๐ง๐ญ๐ฌ ๐ ๐ฅ๐จ๐๐๐ฅ๐ฅ๐ฒ have been treated with PD-1/PD-L1 inhibitors since their introduction.
๐ The global market for PD-1/PD-L1 inhibitors is predicted to reach $110 ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง ๐๐ฒ 2031.
๐ Currently, there are 9 FDA-approved PD-1/PD-L1 inhibitors:
โ Keytruda (pembrolizumab) โ Merck
โ Opdivo (nivolumab) โ Bristol Myers Squibb
โ Tecentriq (atezolizumab) โ Roche/Genentech
โ Imfinzi (durvalumab) โ AstraZeneca
โ Bavencio (avelumab) โ Merck Group/Pfizer
โ Libtayo (cemiplimab) โ Regeneron/Sanofi
โ Jemperli (dostarlimab) โ GSK
โ Zynyz (retifanlimab) โ Incyte
โ Loqtorzi (toripalimab) โ Coherus BioSciences/Shanghai Junshiโฆ